Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) COO Eben Tessari Sells 45,042 Shares

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) COO Eben Tessari sold 45,042 shares of the stock in a transaction that occurred on Wednesday, June 11th. The stock was sold at an average price of $30.51, for a total value of $1,374,231.42. Following the sale, the chief operating officer now directly owns 72,363 shares in the company, valued at $2,207,795.13. This represents a 38.36% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Eben Tessari also recently made the following trade(s):

• On Monday, June 9th, Eben Tessari sold 10,319 shares of Kiniksa Pharmaceuticals stock. The stock was sold at an average price of $30.38, for a total transaction of $313,491.22.
• On Tuesday, June 10th, Eben Tessari sold 15,506 shares of Kiniksa Pharmaceuticals stock. The shares were sold at an average price of $30.46, for a total transaction of $472,312.76.
• On Monday, May 19th, Eben Tessari sold 12,000 shares of Kiniksa Pharmaceuticals stock. The stock was sold at an average price of $26.41, for a total transaction of $316,920.00.
• On Monday, April 14th, Eben Tessari sold 12,000 shares of Kiniksa Pharmaceuticals stock. The shares were sold at an average price of $20.48, for a total value of $245,760.00.

Kiniksa Pharmaceuticals Stock Up 1.5%

Shares of KNSA stock opened at $30.22 on Thursday. Kiniksa Pharmaceuticals, Ltd. has a twelve month low of $17.38 and a twelve month high of $30.69. The stock’s fifty day simple moving average is $24.80 and its 200 day simple moving average is $22.08. The firm has a market capitalization of $2.21 billion, a P/E ratio of -215.84 and a beta of 0.06.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last released its quarterly earnings data on Tuesday, April 29th. The company reported $0.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.02 by $0.09. Kiniksa Pharmaceuticals had a negative return on equity of 7.31% and a negative net margin of 2.36%. The company had revenue of $137.79 million during the quarter, compared to the consensus estimate of $128.35 million. During the same quarter in the prior year, the firm posted ($0.25) earnings per share. The firm’s revenue was up 72.5% compared to the same quarter last year. As a group, equities research analysts expect that Kiniksa Pharmaceuticals, Ltd. will post -0.55 EPS for the current fiscal year.

Analysts Set New Price Targets

KNSA has been the subject of a number of research analyst reports. Citigroup initiated coverage on Kiniksa Pharmaceuticals in a research report on Thursday, March 13th. They set a “buy” rating and a $40.00 price objective for the company. Jefferies Financial Group boosted their target price on Kiniksa Pharmaceuticals from $40.00 to $45.00 and gave the stock a “buy” rating in a research note on Tuesday, April 29th. Wall Street Zen downgraded shares of Kiniksa Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, June 6th. Finally, Wedbush reaffirmed an “outperform” rating and set a $34.00 price target on shares of Kiniksa Pharmaceuticals in a report on Wednesday, April 16th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $38.80.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the business. GAMMA Investing LLC lifted its holdings in shares of Kiniksa Pharmaceuticals by 84.8% during the first quarter. GAMMA Investing LLC now owns 1,238 shares of the company’s stock worth $27,000 after purchasing an additional 568 shares during the period. US Bancorp DE bought a new position in Kiniksa Pharmaceuticals during the 1st quarter worth $33,000. Asset Management One Co. Ltd. bought a new position in Kiniksa Pharmaceuticals during the 1st quarter worth $41,000. Wealthquest Corp acquired a new position in Kiniksa Pharmaceuticals during the 1st quarter worth about $42,000. Finally, Lazard Asset Management LLC bought a new stake in shares of Kiniksa Pharmaceuticals in the 4th quarter valued at about $61,000. 53.95% of the stock is owned by institutional investors.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.